Pharma Stocks
-
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…
Read More » -
Should You Reconsider Bristol-Myers After Shares Drop 21% Amid Pharma Tariff Uncertainty?
So you are staring at Bristol-Myers Squibb’s ticker and wondering if now is the time to make a move. When…
Read More » -
Can EMCOR’s Healthcare and Pharma Projects Drive Future Upside?
Besides data center construction projects, EMCOR Group, Inc. EME is witnessing growing demand in the healthcare and pharma-related projects. These…
Read More » -
European Pharma And Biotech Stocks Outpace The Pack
What’s going on here? European pharma and biotech stocks took the spotlight this week, boosting the S&P Europe Select ADR…
Read More » -
Is Weakness In Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Amphastar Pharmaceuticals (NASDAQ:AMPH) has had a rough month with its share price down 9.3%. However, stock prices are usually driven…
Read More » -
Reviva Pharmaceuticals Announces Public Stock & Warrant Offering
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory…
Read More » -
Reviva Pharma Prices $9M Public Offering of Common Stock
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory…
Read More » -
individual investors who own 51% along with institutions invested in Clarity Pharmaceuticals Ltd (ASX:CU6) saw increase in their holdings value last week
Key Insights Clarity Pharmaceuticals’ significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger…
Read More » -
Astellas Pharma’s (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year’s
Astellas Pharma Inc. (TSE:4503) has announced that it will be increasing its dividend from last year’s comparable payment on the…
Read More » -
Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
It’s not a stretch to say that Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) price-to-sales (or “P/S”) ratio of 8.7x right now seems…
Read More »